229111 Innovative Approaches to Therapeutic HIV vaccine Design

Wednesday, November 10, 2010 : 1:45 PM - 2:00 PM

Richard Ogden, PhD , Tobera Therapeutics, Princeton, NJ
Topic:  HIV Vaccine Development Abstract: Innovative Approaches to Therapeutic HIV vaccine Design

Issues Unprecedented rates of antiretroviral drug resistance demand the development of new therapies for treatment experienced HIV patients experiencing the pathogenesis of resistant profiles of minority subspecies. Clinical developments in the field of therapeutic vaccines for HIV have clearly indicated significant therapeutic response for patients on salvage therapy who are currently without viable clinical options.

Description This roundtable discussion will provides an overview of therapeutic approaches currently in clinical development that could succeed in suppressing viral replication and delaying disease progression with structured treatment interruptions.   Specific therapeutic HIV vaccine approaches: - autologous dendritic cell therapy - p24 like peptide vaccine - DNA plasmid vaccine - lentiviral vector gene therapy

Lessons Learned Neither HAART nor a preventive vaccine is expected to provide a solution to the HIV epidemic within the next decade  It is therefore necessary to refocus on the development of immune-based therapies to achieve viral suppression and CD4 reconstitution in the absence of antiretroviral therapy.

Recommendations Several therapeutic HIV vaccine strategies show significant promise in treatment experienced patients and would provide alternatives for patient populations who are experiencing and increasingly developing extensive antiretroviral drug resistance and demonstrate inability to achieve viral suppression through HAART. Further clinical studies in variable patient populations will indicate the efficacy of these approaches for extending the clinical viability of therapeutic HIV vaccine candidates.

Learning Areas:
Basic medical science applied in public health
Clinical medicine applied in public health
Public health biology

Learning Objectives:
Discuss new scientific approaches to therapeutic HIV vaccine design. List two scientific approaches currently in clinical development.

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am qualified to present on the topic because I have directed numerous research efforts in the area of therapeutic HIV vaccine development
Any relevant financial relationships? Yes

Name of Organization Clinical/Research Area Type of relationship
Tobera Therapeutics Antiretroviral therapy Employment (includes retainer)

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.